DEALS: AstraZeneca, AtheroGenics ink $1B licensing deal

DEALS

WHO

WITH

WHAT

SCOOP

AstraZeneca

AtheroGenics

$1B licensing deal

AstraZeneca has rights to AGI-1067, a Phase III drug for the treatment of  atherosclerosis, or hardening of the arteries.

Wyeth

Trubion

$800M development deal

The companies have agreed to develop and market antibody-like drugs for inflammatory diseases and cancer.

AstraZeneca

Targacept

$300M licensing deal

The deal is for Targacept's phase II compound, TC-1734, for Alzheimer's disease, cognitive deficits in schizophrenia and other cognitive disorders.

Exelixis

Wyeth

$157.7M licensing deal

The deal is for the development of treatments for metabolic and liver disorders.

Trubion

Wyeth

$40M collaboration deal

The two companies will work on developing new treatments for inflammatory diseases and cancer.

DUSA

Sirius Labs

$30M buyout

DUSA will pay $8 million in cash and $17 million in stock, with another $5 million in potential payments for new product launches and sales milestones.